C.I Grupex S.A.S
FDA import alert and refusal historyBogota, ColombiaFEI 3016607158
Recorded by FDA as C.I GRUPEX S.A.S
As of October 26, 2026, C.I Grupex S.A.S is not on any FDA import alert in SupplierRadar's records; FDA refused 2 of its shipment lines on September 16, 2022, most often for pesticide chemical residue (PESTICIDE).
Data from FDA public records, last checked . Request a correction
Current status
- Import alerts
- Not listed
- Last import refusal
- Lime (citrus) · PESTICIDE
- Last warning letter
- None found
- Last inspection
- None on record
Every FDA record for C.I Grupex S.A.S
2 records, newest first. Each line links to the FDA page it came from.
Refusal charges, in plain English
- PESTICIDE2 refused lines
Pesticide chemical residue
The product appeared to contain a pesticide chemical residue that makes it adulterated under section 402(a)(2)(B) of the FD&C Act, for example a residue above the U.S. tolerance or one with no U.S. tolerance for that food.
Questions about C.I Grupex S.A.S
- Is C.I Grupex S.A.S on an FDA import alert?
- No listing for C.I Grupex S.A.S appears in the FDA import alerts SupplierRadar checked on October 26, 2026. Country-wide alerts may still apply to its products; see the Colombia page.
- Has FDA refused shipments from C.I Grupex S.A.S?
- Yes. FDA refused 2 shipment lines from C.I Grupex S.A.S on September 16, 2022. The most recent, on September 16, 2022, was lime (citrus), charged as PESTICIDE (pesticide chemical residue).
- Why did FDA refuse C.I Grupex S.A.S's shipments?
- The most frequent charge is PESTICIDE (pesticide chemical residue, 2 lines).
- What is C.I Grupex S.A.S's FEI number?
- C.I Grupex S.A.S's FDA Establishment Identifier (FEI) is 3016607158.
Buying from C.I Grupex S.A.S?
Watch it and get the FDA record the day it changes. Free for one supplier.
SupplierRadar is not affiliated with the U.S. Food and Drug Administration. Data comes from public FDA records and may contain errors. This is not legal advice; importers remain responsible for their supplier evaluations.